{
    "abstract": "Temozolomide (TMZ)-levetiracetam (LEV) combination therapy in glioblastoma management is gradually becoming a mainstay treatment given its superior effect compared with TMZ monotherapy. While there have been previous cases of hepatotoxicity, there are no prior reports of vanishing bile duct syndrome (VBDS) associated with TMZ-LEV combination use. This case report details a male in his 50s who had recently completed TMZ and LEV for right frontal lobe glioblastoma. He presented 3\u2009days later with painless jaundice, dark urine and pale stools. Laboratory evaluation was remarkable for marked hyperbilirubinemia and transaminitis. Extensive work up for hepatic and extra-hepatic causes of jaundice was of no yield, thus necessitating a liver biopsy. Liver pathology showed a non-specific histomorphology pattern suggesting drug-induced liver injury and cholestasis with severe ductopenia. VBDS due to TMZ and LEV was diagnosed. The patient followed with the gastroenterology clinic over 6 months for persistently elevated liver function tests before suffering a fatal cardiac arrest.",
    "authors": [
        {
            "affiliation": "Medical School, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota, USA lindsey.martens@und.edu.",
            "firstname": "Lindsey",
            "initials": "L",
            "lastname": "Martens"
        },
        {
            "affiliation": "Internal Medicine, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota, USA.",
            "firstname": "Olawale",
            "initials": "O",
            "lastname": "Babalola"
        },
        {
            "affiliation": "Essentia Health West Region, Fargo, North Dakota, USA.",
            "firstname": "Awais",
            "initials": "A",
            "lastname": "Aslam"
        },
        {
            "affiliation": "Essentia Health Fargo Hospital, Fargo, North Dakota, USA.",
            "firstname": "Rabiah",
            "initials": "R",
            "lastname": "Ashraf"
        }
    ],
    "conclusions": null,
    "copyrights": "\u00a9 BMJ Publishing Group Limited 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
    "doi": "10.1136/bcr-2024-260830\n10.1097/MD.0000000000000476\n10.1186/s13063-022-06168-1\n10.1016/j.dld.2016.11.015\n10.1684/bdc.2009.0865\n10.3174/ajnr.A2170\n10.2165/11204490-000000000-00000\n10.12688/f1000research.18198.1\n10.1212/01.wnl.0000324604.11657.c6\n10.4236/crcm.2012.12010\n10.1515/dmdi-2013-0006\n10.1186/s12935-018-0626-8\n10.1155/2013/634174\n10.1097/01.ccm.0000551622.29593.38",
    "journal": "BMJ case reports",
    "keywords": [
        "Cancer intervention",
        "Contraindications and precautions",
        "Drug interactions",
        "Gastrointestinal system",
        "Jaundice"
    ],
    "methods": null,
    "publication_date": "2024-11-15",
    "pubmed_id": "39542501\n31643176\n25816026\n35346332\n28034663\n32491467\n31643176\n21874146\n31643176\n19467988\n20538821\n21395360\n31643176\n30984385\n18725594\n23420283\n30214378\n31689026\n29489165\n31643176\n24027645",
    "results": null,
    "title": "Vanishing bile duct syndrome: a sequela of temozolomide and levetiracetam-induced cholestatic liver injury.",
    "xml": "<Element 'PubmedArticle' at 0x788502f37f60>"
}